Search Criteria: Research Area is "Cancer Research: Increased Tumor Incidence (Hepatomas: hepatacellular carcinoma)"

New Strains Under Development

JAX® Mice Strains

Stock
Number
Strain Name
 
Strain Description
Standard Supply
005143 C3.B6-Tg(Fabp1-Ccnd1)4Rdb/J
Repository-Cryopreserved
These transgenic mice express mouse cyclin D1 under the direction of the rat fatty acid binding protein 1 promoter (-596 to +21 fragment). Mice that are hemizygous for the transgene are viable, normal in size and do not display any gross physical or behavioral abnormalities. Hemizygous mutant mice exhibit reduced fertility after 3 months of age. Transgenic mice overexpress cyclin D1 in the liver and epithelial cells of the small intestine and colon. A lower level of expression occurs in the kidneys. Onset of progressive liver disease begins at one month of age with hepatomegaly. Male transgenic mice exhibit more severe hepatomegaly than transgenic females. By 6 months of age, all transgenic males and half of the transgenic females display hepatocellular dysplasia. Eighty-seven percent of transgenic males and 69% of transgenic females develop hepatocellular adenoma or hepatocellular carcinoma by 15 months of age. This mutant mouse strain may be useful in studies of hepatocellular carcin .....
For more information please see the full descriiption on the strain data sheet
004834 C57BL/6-Tg(Fabp1-Ccnd1)4Rdb/J
Repository-Cryopreserved
These transgenic mice express the mouse cyclin D1 under the direction of the rat fatty acid binding protein 1 promoter (–596 to +21 fragment). Mice that are hemizygous for the transgene are viable, normal in size and do not display any gross physical or behavioral abnormalities. Hemizygous mutant mice exhibit reduced fertility after 3 months of age. Transgenic mice overexpress cyclin D1 in the liver and epithelial cells of the small intestine and colon. A lower level of expression occurs in the kidneys. Onset of progressive liver disease begins at one month of age with hepatomegaly. Male transgenic mice exhibit more severe hepatomegaly than transgenic females. By 6 months of age, all transgenic males and half of the transgenic females display hepatocellular dysplasia. 87% of transgenic males and 69% of transgenic females develop hepatocellular adenoma or hepatocellular carcinoma by 15 months of age. By 6 months of age, approximately half of mutant mice have lost hepatic expressio .....
For more information please see the full descriiption on the strain data sheet
002226 C57BL/6J-Tg(Alb1HBV)44Bri/J
Repository-Cryopreserved
This strain is referred to as "50-4" or "Tg(Alb1-HBV)Bri44" in the primary reference.
002539 FVB.129P2-Abcb4tm1Bor/J
Repository-Cryopreserved
Mice homozygous for the Abcb4tm1Bor mutation lack the ability to secrete phospholipid into the bile from the liver. They develop a degenerative liver disease. Portal inflammation ensues at an early age followed by hepatocellular carcinoma development after the age of 1 year. Bile from heterozygous mice has half the level of phospholipid when compared to bile from homozygotes. No liver pathology has been shown in heterozygotes.

(4 stocks)         Back to Top

New Strains Under Development

(See informational text following listing of strains)
How to Register Interest
Please indicate your interest in purchasing any of the strains listed below when they become available for distribution by checking the box next to the strain(s) of interest and then selecting the "Continue" button which leads to an Interest Form.

View a Data sheet for New Strains Under Development
Select the strain name to link to the strain data sheet.

Stock
Number
Strain Name
 
Strain Description
Standard Supply
008190B6;129S2-Nf2tm1Tyj/J
Under Development for Production
Most embryos that are homozygous for this targeted mutation fail between embryonic days 6.5 and 7.0, exhibiting a collapsed extraembryonic region and the absence of organized extraembryonic ectoderm. The embryo proper continues to develop, but fails to initiate gastrulation. Heterozygotes develop a variety of malignant tumors over the course of 10-30 months, including osteosarcoma (63%), lymphoma (15%), lung adenocarcinoma (10%), hepatocellular carcinoma (9%), and fibrosarcoma (9%). A high rate of metastasis to distant sites such as the lung and liver was found. Schwannomas, meningiomas and ependymomas were not detected. RT-PCR analysis and sequencing of the product have shown that a mutant form of mRNA is transcribed and spliced. Immunoblotting fails to detect any full-length or shortened protein products, however. This strain may be useful in studies of embryonic development and cancer.

(1 stocks)         Back to Top

New Strains Under Development The Jackson Laboratory serves as a worldwide distributor and national repository for common and rare strains of inbred mice and mice carrying spontaneous mutations or induced mutations (i.e., transgenic, targeted/"knockout", or chemically induced mutations). At any one time, we have over 100 strains at various stages of development and colony expansion. Strains "Under Development" fall into two categories depending on the anticipated demand from the scientific community.
  1. Strains that will be made available from a live distribution colony at The Jackson Laboratory.
    These strains are designated as: "Under Development for Distribution Colony"
  2. Strains that will be made available through the Cryopreservation Repository.
    These strains are designated as: "Under Development for Cryopreservation Repository"
It is VERY IMPORTANT that you register interest in strains Under Development. The anticipated demand for a strain enables us to determine effectively the distribution plan for each strain Under Development. Registering interest also provides benefits to you (including advance notification of pending availability). Whether a strain is made available from a live colony OR from our cryopreservation repository, you may want to consider the option of Dedicated Supply. To learn more about Dedicated Supply, go to Services.

Back to top


Send questions to our Technical Support team using the Express Technical Support Form.
(3.2)